Cellectis has entered into a joint research collaboration agreement and investment agreement with AstraZeneca, relating to an initial equity investment of $80 million, and a memorandum of understanding relating to an additional equity investment of $140 million. The agreement aims to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology, and rare diseases. AstraZeneca will leverage Cellectis’ gene editing technologies and manufa...